Genes Laboratories
Genes Laboratories is a South Korean molecular diagnostics company developing PCR-based kits for human infectious and genetic diseases, companion animal diagnostics, and PCR reagents, operating as the molecular diagnostics arm of GC Green Cross.
- Company typePrivate
- Founded2008
- HeadquartersYongin, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genes Laboratories does
Genes Laboratories (진스랩) is a South Korea-based molecular diagnostics company founded on November 4, 2008, with headquarters in Seongnam-si, Gyeonggi-do, and an additional R&D facility in Yongin-si. The company develops, manufactures, and commercializes PCR-based diagnostic kits and reagents across three brand families: GCdia™ human diagnostic kits covering infectious diseases (respiratory infections, sexually transmitted infections, gastrointestinal infections, pneumonia, hepatitis, tuberculosis), genetic disorders (HLA typing for transplant compatibility and disease association, ApoE genotyping for Alzheimer's risk), and pharmacogenomics (HLA-B*58:01 for drug hypersensitivity); GCani™ veterinary diagnostic kits for canine and feline companion animal diseases plus zoonotic pathogens (SFTSV, Babesia, Salmonella); and NEXpro™/NEXscript™ brand PCR enzymes, master mixes, and reverse-transcription reagents sold to other diagnostic manufacturers and research institutions.
The company's technology platform centers on multiplex quantitative real-time PCR (qPCR) and qRT-PCR using fluorescent probe-based detection, supported by proprietary enzyme chemistry including a monoclonal antibody-based hot-start Taq DNA polymerase (NEXpro™ HS Taq) and a UDG-containing qRT-PCR master mix designed to suppress non-specific amplification. As of 2023 the company held over 10 patents, had a 12-product development pipeline, and maintained 25+ export approvals for animal and zoonotic diagnostic reagents, three MFDS-approved genetic disease kits, and certifications including ISO 13485, KGMP, ISO 9001, GMP, and European CE Mark (for COVID-19 reagents).
Genes Laboratories has been part of the GC Green Cross (GC녹십자) healthcare conglomerate family since 2021, operating as the group's designated molecular diagnostics representative. It sells primarily through direct sales to hospitals, clinical diagnostic laboratories, and veterinary clinics, supplemented by international export channels and a November 2025 domestic distribution agreement with Inpeco for Total Laboratory Automation (TLA) solutions. Pricing is not publicly disclosed. Revenue is not disclosed in source data; with 1-10 employees per firmographics, the company operates a lean team despite its broad product portfolio. Current CEO Woo Byeong-ho (우병호) was appointed in 2024 following the resignation of Jang Uk-jin (장욱진).
Genes Laboratories firmographics
Firmographics- Name
- Genes Laboratories
- Legal name
- 주식회사 진스랩
- Website
- https://geneslabs.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Genes Laboratories is a South Korean molecular diagnostics company developing PCR-based kits for human infectious and genetic diseases, companion animal diagnostics, and PCR reagents, operating as the molecular diagnostics arm of GC Green Cross.
- Ownership category
- akta.pro rank
Genes Laboratories industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where Genes Laboratories is headquartered
LocationHeadquarters
- HQ city
- Yongin
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Genes Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Human Diagnostic Kits: Sale of multiplex qPCR detection kits for human infectious diseases (respiratory infections, sexually transmitted infections, gastrointestinal infections, tuberculosis, pneumonia) and genetic disorders (HLA typing, ApoE genotyping). Revenue from regulatory-approved in vitro diagnostic medical devices sold domestically (MFDS-approved) and for export.
- Veterinary Diagnostic Kits: Sale of multiplex qPCR/qRT-PCR detection kits for companion animals (dogs and cats) and zoonotic diseases, including products for export to multiple countries. Veterinary medical device sales.
- PCR Raw Materials and Reagents: Sale of PCR enzymes, master mixes, and nucleic acid extraction kits to other diagnostic manufacturers and laboratories. Global supply of molecular diagnostic-grade raw materials including DNA polymerases, reverse transcriptases, and optimized buffer systems.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Genes Laboratories product offering
Product offeringCore offering
Genes Laboratories develops, manufactures, and commercializes PCR-based molecular diagnostic kits and reagents. Its portfolio spans three lines: GCdia™ human diagnostic kits (respiratory, sexually transmitted, gastrointestinal, pneumonia, hepatitis, tuberculosis, and genetic disease panels such as HLA typing and ApoE genotyping), GCani™ companion-animal and zoonotic diagnostic kits for canines, felines, and zoonotic pathogens (SFTSV, Babesia, Salmonella), and NEXpro™/NEXscript™ brand PCR raw materials (DNA polymerases, hot-start Taq, reverse transcriptases, master mixes, and nucleic extraction reagents) sold to other diagnostic manufacturers and research labs.
Product overview
Genes Laboratories is a molecular diagnostics company that develops, manufactures, and commercializes PCR-based diagnostic kits for human infectious diseases, genetic diseases, veterinary (companion animal and zoonotic) diseases, and PCR reagents/raw materials. The product portfolio includes three main product lines: (1) GCdia™ brand human diagnostic kits covering infectious diseases (respiratory infections, sexually transmitted infections, gastrointestinal infections, tuberculosis, pneumonia), genetic diseases (HLA typing for transplant compatibility, ApoE genotyping for Alzheimer's disease), and pharmacogenomics (HLA-B*58:01); (2) GCani™ brand veterinary diagnostic kits for canine and feline diseases across gastrointestinal, hematological, respiratory, and neurological categories, plus zoonotic pathogens (SFTSV, Babesia, Salmonella); and (3) NEXpro™ and NEXscript™ brand PCR reagents and enzymes for research and diagnostic manufacturing applications. The company also offers diagnostic systems including lab automation equipment, point-of-care testing devices, and a mobile diagnostic laboratory (GCdia Mobile Base Camp). All products are based on molecular diagnostic technologies including conventional PCR, real-time PCR (qPCR), RT-PCR, and qRT-PCR using fluorescent probe-based detection methods.
Differentiator
Problem solved
Functional benefit
Brands
- GCdia™: Human diagnostics product brand for infectious and genetic disease molecular diagnostic kits including GCdia™ MTB/NTM Real-Time PCR Kit, GCdia™ HLA-B27, GCdia™ ApoE Genotyping Kit, GCdia™ Pneumocystis jirovecii Real-Time PCR Kit, and others.
- GCani™
- NEXpro™
- NEXscript™
Products and services
- GCdia™ Human Infectious Disease Real-Time PCR Kits Multiplex real-time PCR kits for qualitative detection of human infectious disease pathogens from clinical specimens such as sputum, nasopharyngeal swabs, blood, urine, and tissue samples. Intended for hospitals and clinical diagnostic laboratories.
- GCdia™ Human Genetic Disease Real-Time PCR Kits Real-time PCR kits for HLA typing for transplant compatibility and pharmacogenomics (HLA-B27, HLA-B51, HLA-B*58:01 for allopurinol hypersensitivity), and ApoE genotyping for Alzheimer's disease and cardiovascular risk. Sold to clinical labs and hospitals.
- GCani™ Canine Disease Multiplex qPCR/qRT-PCR Detection Kits Multiplex real-time PCR kits for qualitative detection of canine pathogens causing diarrhea (bacterial and viral panels), anemia (bacterial panels), respiratory infections, and neurological diseases. Used by veterinary hospitals and animal diagnostic laboratories.
- GCani™ Feline Disease Multiplex qPCR/qRT-PCR Detection Kits Multiplex real-time PCR kits for qualitative detection of feline pathogens causing diarrhea, anemia, respiratory infections, neurological disease, and Feline Coronavirus (FCoV). Used by veterinary hospitals and animal diagnostic laboratories.
- GCani™ Zoonotic Disease Detection Kits Multiplex real-time PCR kits for detection of zoonotic pathogens including Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), Babesia species, and Salmonella in animal samples. Used by veterinary clinics and public health/animal health laboratories.
- NEXpro™ PCR Enzymes and Master Mixes PCR enzymes and ready-to-use 2X master mixes for conventional PCR, real-time PCR, and qRT-PCR applications. Hot-start Taq formulations with monoclonal antibody inhibition reduce non-specific amplification. Sold to diagnostic kit manufacturers, biotech firms, and research laboratories globally.
- NEXscript™ Reverse Transcription and RT-PCR Reagents Reverse transcription master mixes and one-step RT-PCR reagents for cDNA synthesis from RNA templates. Includes formulations with Oligo dT primers, random hexamers, and combined RT-PCR with fluorescent dye. Sold to diagnostic manufacturers and research labs.
- Diagnostic Systems (Point-of-Care and Lab Automation) Hardware diagnostic systems comprising a mobile diagnostic laboratory (GCdia Mobile Base Camp), production and extraction automation equipment, and a point-of-care molecular diagnostic testing device for rapid bedside or field diagnosis.
- COVID-19 Diagnostic Reagent Real-time PCR kit (GCdia™ COVID-19 Fast Detection Kit) for detection of two target genes of SARS-CoV-2 from nasopharyngeal swab, oropharyngeal swab, and sputum samples. CE-Marked for export and MFDS-approved domestically.
Quantifiable outcome
- 25+ animal and zoonotic disease diagnostic reagents received export approval in 2023, enabling international market presence
- +2 more outcomes
Companies that use Genes Laboratories
Customer profileSegments3 records
Ideal customer profiles3 records
Genes Laboratories technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Genes Laboratories partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Inpeco (인페코)coreGenes Laboratories signed an official domestic distribution agreement with Inpeco in November 2025. Inpeco serves as the official distributor for TLA (Total Laboratory Automation) solutions and provides associated technical support to customers in South Korea.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Genes Laboratories competitors and assessment
Company assessmentBroad incumbents
- Hologic (Panther Fusion): US-headquartered molecular diagnostics incumbent with Panther Fusion menu covering respiratory, STI, and other infectious disease targets; broad incumbent competitor in clinical molecular testing.
- Qiagen: Global leader in molecular diagnostics and PCR enzymes/reagents; competes with Genes Laboratories' NEXpro™/NEXscript™ raw materials offering and broader IVD menu, but at much larger scale and global reach.
- Roche Diagnostics: Global IVD incumbent with extensive molecular diagnostics portfolio (cobas, LightCycler); competes broadly with Genes Laboratories in clinical lab infectious disease and genetic testing markets.
- Cepheid (Danaher): Leader in automated molecular diagnostics (GeneXpert) with broad infectious disease menu; competing incumbent for hospital and lab customers targeted by Genes Laboratories' multiplex qPCR kits.
- bioMérieux (BioFire): Global molecular diagnostics player via BioFire FilmArray syndromic panels; competes with Genes Laboratories in multiplex infectious disease testing for clinical laboratories.
Direct peers
- Kogene Biotech: Korean PCR-based IVD developer offering infectious disease diagnostic kits and reagents; directly comparable product categories (respiratory, STI, GI) and Korean regulatory positioning.
- Seegene: Korean molecular diagnostics company specializing in multiplex qPCR reagents and syndromic panels for infectious disease and genetic testing — directly comparable technology stack and customer base (clinical labs and hospitals) to Genes Laboratories.
- SD Biosensor: Korean in-vitro diagnostics company offering molecular (PCR) and rapid antigen kits for infectious diseases with strong export footprint; comparable IVD product lines and channel approach.
- SolGent (SolGent Daejeon): Korean molecular diagnostics manufacturer of qPCR/RT-PCR kits for infectious disease and genetic testing; comparable multiplex assay technology and IVD regulatory profile in Korea.
Emerging players
- Bioneer: Korean molecular diagnostics and life science tools company with PCR instruments and AccuPower reagent kits; comparable Asian footprint and reagent product lines to Genes Laboratories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Genes Laboratories social profiles
Digital presenceGenes Laboratories compliance and trust
Trust signalCompliance5 records
Genes Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genes Laboratories leadership team
Management profileNumber of profiles
Profiles1 record
Genes Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genes Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genes Laboratories
What does Genes Laboratories do?
Genes Laboratories develops, manufactures, and commercializes PCR-based molecular diagnostic kits and reagents. Its portfolio spans three lines: GCdia™ human diagnostic kits (respiratory, sexually transmitted, gastrointestinal, pneumonia, hepatitis, tuberculosis, and genetic disease panels such as HLA typing and ApoE genotyping), GCani™ companion-animal and zoonotic diagnostic kits for canines, felines, and zoonotic pathogens (SFTSV, Babesia, Salmonella), and NEXpro™/NEXscript™ brand PCR raw materials (DNA polymerases, hot-start Taq, reverse transcriptases, master mixes, and nucleic extraction reagents) sold to other diagnostic manufacturers and research labs.
Is Genes Laboratories a public or private company?
Genes Laboratories is a private company. It is classified as corporate owned and is currently operating.
When was Genes Laboratories founded?
Genes Laboratories was founded in 2008. It employs 1 to 10 people.
Where is Genes Laboratories based?
Genes Laboratories is headquartered in Yongin, South Korea, in the Asia region.
How does Genes Laboratories make money?
Three revenue lines are on record. Human Diagnostic Kits are the primary driver. The others are veterinary Diagnostic Kits and PCR Raw Materials and Reagents.
Who are Genes Laboratories's main competitors?
Broad incumbents on record are Hologic (Panther Fusion), Qiagen, Roche Diagnostics, Cepheid (Danaher) and bioMérieux (BioFire). Direct peers are Kogene Biotech, Seegene, SD Biosensor and SolGent (SolGent Daejeon). Bioneer is listed as an emerging player.
Does Genes Laboratories have an API?
No public API is recorded for Genes Laboratories.
What industry is Genes Laboratories in?
Genes Laboratories's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.